Dr. Gil Van Bokkelen, founder and CEO, Athersys a clinical stage biotech company, talks about developing cell therapies and regenerative medicine as alternatives to conventional standards of medical intervention and treatment using their MultiStem cell therapy platform.  Gil explains how gene therapies work by providing multi-dimensional solutions and how they differ from traditional pharmaceuticals or […]

After accumulating more than 30 years of biopharma experience, Jose Iglesias has been named CMO of Senti Biosciences, a gene circuit company based in the San Francisco area. Iglesias is slated to lead Senti’s clinical development programs with an emphasis on treating solid and liquid tumors. Iglesias designed the cancer drug Abraxane while he was […]

Trovagene is exploring the activity of its PLK1 inhibitor onvansertib in three biomarker-defined cancer indications and, based on […]